New interesting findings for the tumor marker UBC® Rapid | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

March 2016

New interesting findings for the tumor marker UBC® Rapid

Result from a new German multicenter study

At this year’s EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on UBC® Rapid was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital, Department of Urology, Bad Sarrow. Urine samples were analyzed by UBC®Rapid POC test and evaluated quantitatively. The study showed very high sensitivity and specificity for high grade tumors generally 71/94%, and for CIS patients the sensitivity was even higher 87%.The authors concluded that UBC® Rapid should be added in the diagnostics for high risk bladder cancer and in particular for CIS patients with tumors in the bladder.

 

IDL Biotech förbereder kliniska studier i USA för sitt snabbtest för blåscancer, UBC® Rapid

Under 2019 lämnade IDL Biotech in underlag, en så kallad ”pre-submission request”, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande av UBC® Rapid, bolagets snabbtest för blåscancer. Nu går bolaget vidare och förbereder kliniska studier i USA.

Gunnar Wahlberg appointed as acting CEO

The Board has appointed Gunnar Wahlberg as acting CEO.

IDL Biotech

Skip this intro